Adriana Vela, PhD is a biochemist who transitioned from the laboratory setting to leading scientific and medical communication about targeted therapies in oncology. She currently serves as Vice President of Medical Affairs and Operations at ArteraAI where she and her team are communicating to clinicians the value of artificial intelligence-based tests for prognostic outcomes and predictive benefit to a particular therapy in localized prostate cancer.
Prior to joining ArteraAI, Adriana was a Senior Medical Science Liaison at AstraZeneca and Bayer and worked closely with research institutions on clinical trial development in GU cancers. Prior to her work in the pharmaceutical industry, she advised Medical Affairs teams in pharmaceutical and biotechnology companies on content development and brand strategy across various types of cancers in Medical Communication agencies such as Synapse, BGB, and DDB Health.
She obtained her PhD in Molecular Biophysics and Biochemistry from Yale, where her research was focused on protein-viral RNA interactions and high-throughput drug screening. She then went on to conduct translational research at the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center to determine the efficacy of radiation therapy in combination with PARP inhibitors to enhance synthetic lethality in breast cancer models.